Investor focus will likely be on the sales performance of ABBV's blockbuster immunology drugs, Rinvoq and Skyrizi, when it ...

AbbVie has returned to the source of its antipsychotic powerhouse Vraylar in search of another blockbuster, paying $25 ...

AbbVie has entered a collaboration with Gedeon Richter (Richter) to develop new treatments for neuropsychiatric conditions.

Citi raised the firm’s price target on AbbVie (ABBV) to $215 from $170 and keeps a Buy rating on the shares following a transfer of ...

Dividend stocks can be valuable investments for retirees who want a consistent stream of income flowing into their portfolio ...

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for AbbVie (ABBV), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the ...

AbbVie should report strong Q3 2024 results next week and increase the full-year guidance. Explore more details here.

Valuation metrics show AbbVie to be only slightly undervalued based on FY 2025 projections. Read why I'm neutral on ABBV ...

Argent Capital Management LLC reduced its holdings in AbbVie Inc. (NYSE:ABBV – Free Report) by 96.3% in the 3rd quarter, ...

AbbVie (ABBV) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the ...

Through a partnership, a third Waco ISD school will receive a new STEM lab for students to get hands-on experience.

In the closing of the recent trading day, AbbVie (ABBV) stood at $189.65, denoting a +0.94% change from the preceding trading day.